By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Resverlogix Corporation 

4820 Richard Road SW
Suite 300
Calgary  Alberta  T3E 6L1  Canada
Phone: 403-254-9252 Fax: 403-256-8495


Company News
Resverlogix (RVX.TO) Announces Filing Of Quarterly Financial Statements And Management's Discussion & Analysis 9/14/2017 10:59:45 AM
Resverlogix (RVX.TO) Closes Extension Of Maturity Date Of Loan And Announces Private Placement 9/5/2017 10:04:15 AM
Resverlogix (RVX.TO) Announces Extension Of Maturity Date Of Loan And Expression Of Interest Regarding Strategic Transaction 8/28/2017 7:19:37 AM
Resverlogix (RVX.TO) Receives Approval Pathway From The FDA As To The Inclusion Of USA Patients In The Phase III BETonMACE Trial 7/25/2017 7:22:08 AM
Resverlogix (RVX.TO) And Hepalink Start Taiwan/China Trial Of CVD/Diabetes Treatment 7/11/2017 1:06:47 PM
Resverlogix (RVX.TO) Randomizes First Patient In Taiwan/China Portion Of The Phase III BETonMACE Clinical Trial 7/10/2017 6:26:53 AM
Resverlogix (RVX.TO) Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase III Study Of Apabetalone 6/28/2017 6:36:29 AM
Resverlogix (RVX.TO) Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone 5/30/2017 6:12:38 AM
Resverlogix (RVX.TO) Release: Recent Publication And Patent Application Referencing Apabetalone Support Its Continued Development And Success 5/23/2017 7:34:58 AM
Resverlogix (RVX.TO) Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial 5/15/2017 9:34:02 AM